For Healthcare Professionals

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

clipboard-pencil

About the study

The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC) and liver metastases for colon cancer (mCRC) in real world clinical practice settings in France.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

EXCLUSION CRITERIA

  • Inclusion:
    1. Participant has received a reimbursed dose of TheraSphere®
    2. Participant does not oppose to the collection of his/her medical personal data

    Exclusion:


    1. Participant has opposed to data collection
    2. Participant has not received a reimbursed dose of TheraSphere® (free of charge dose)

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply


    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Contition

    Hepatocellular Carcinoma

    Age (in years)

    18+

    Participants needed

    500

    Est. Completion Date

    Jan 1, 2025

    Treatment type

    Observational [Patient Registry]


    Sponsor

    Boston Scientific Corporation

    ClinicalTrials.gov identifier

    NCT04069468

    Study number

    BTG-007996-01

    Understanding Clinical Trials


    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
    Vector

    Interested?

    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.